Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCIN-UTI is a marketed pharmaceutical product developed by Vin Medicament, primarily indicated for the management and prevention of urinary tract infections (UTIs). While specific formulation details for this exact brand name are limited in clinical literature, products labeled for UTI management by generic manufacturers in the Indian market typically consist of either a single-agent antibiotic (such as nitrofurantoin or fosfomycin) or a combination of nutraceuticals and urinary alkalizers designed to alleviate symptoms and inhibit bacterial adherence. Common ingredients in such formulations include cranberry extract (proanthocyanidins), D-mannose, and potassium magnesium citrate. Cranberry and D-mannose work by preventing *Escherichia coli* from adhering to the uroepithelial cells, while alkalizers help reduce the acidity of urine to relieve dysuria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VCIN-UTI.